Company: ENTXW
Filing Date: 2025-05-14
Form Type: PRE 14A
Source: 0001178913-25-001794
Chunk: 11

Company: Entera Bio Ltd.
Filing Date: 2025-05-14
Form: PRE 14A
Chunk 11
---
 obtained his PhD. in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of the Hebrew University of Jerusalem. 6 Dana Yaacov-Garbelihas served as our Chief Financial Officer since June 2019. Ms. Yaacov-Garbeli has over 17 years of finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She has significant experience in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel. Hillel Galitzer, PhDhas served as our Chief Operating Officer since February 2014, prior to which he served as our Director of Scientific Development from July 2010. Prior to joining Entera, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of Optivasive Inc. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem. Leslie Gautamhas over 20 years of experience in healthcare with extensive strategic advisory experience across biopharma, in both clinical and commercial stage companies with a particular focus in specialty therapeutic categories, including women’s health and supportive care. In December 2023, Ms. Gautam co-founded and was CEO of an early-stage women’s health company that provided care delivery and innovation for patients with hyperemesis gravidarum. From October 2019 to November 2023, Ms. Gautam served as a senior member of the Healthcare investment banking team at Stifel (via acquisition of Torreya Capital) where she provided strategic advice on a variety of biopharma transactions, including M&A, independent Board advice and capital raising. Ms. Gautam was a senior banker at Houlihan Lo